These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 36714649)

  • 1. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
    Kong W; Mao W; Zhang L; Wu Y
    Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study.
    Wu J; Wu J; Tang B; Wang X; Wei F; Zhang Y; Li L; Li H; Wang B; Wu W; Hong X
    Front Pharmacol; 2024; 15():1399172. PubMed ID: 39309013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system.
    Shen J; Luo P; Xu J
    Ther Adv Drug Saf; 2024; 15():20420986241278498. PubMed ID: 39376495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database.
    Xu H; Xu N; Wang Y; Zou H; Wu S
    Front Pharmacol; 2024; 15():1442002. PubMed ID: 39188956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor.
    Pan Y; Wang Y; Zheng Y; Chen J; Li J
    Front Pharmacol; 2024; 15():1251961. PubMed ID: 38655177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system.
    Jiang T; Su H; Li Y; Wu Y; Ming Y; Li C; Fu R; Feng L; Li Z; Li L; Ni R; Liu Y
    Front Pharmacol; 2022; 13():989032. PubMed ID: 36532784
    [No Abstract]   [Full Text] [Related]  

  • 7. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
    Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
    ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis.
    Jiang A; Wei C; Zhu W; Wu F; Wu B
    Ther Adv Drug Saf; 2024; 15():20420986241244585. PubMed ID: 38715707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.
    Tian X; Chen L; Gai D; He S; Jiang X; Zhang N
    Front Pharmacol; 2022; 13():851246. PubMed ID: 35401230
    [No Abstract]   [Full Text] [Related]  

  • 10. A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS).
    Zhou J; Zhang J; Wang Q; Peng M; Qian Y; Wu F; Rao Q; DanZhen L; Yang Y; Wang S; Liu M
    Ther Adv Drug Saf; 2024; 15():20420986241284105. PubMed ID: 39381060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
    Zhang S; Wang Y; Qi Z; Tong S; Zhu D
    Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS.
    Chai S; Zhan JL; Zhao LM; Liu XD
    Ther Adv Drug Saf; 2022; 13():20420986221143266. PubMed ID: 36545565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
    Yin Y; Shu Y; Zhu J; Li F; Li J
    Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the nervous system and gastrointestinal adverse events associated with solifenacin in older adults using the US FDA adverse event reporting system.
    Nicholls C; Chyou TY; Nishtala PS
    Int J Risk Saf Med; 2023; 34(1):63-73. PubMed ID: 35491805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety evaluation of ceftazidime/avibactam based on FAERS database.
    Zhang X; Jiang Y; Guo Y; Zhou W; Qiao W; Zhu H; Qi Z
    Infection; 2024 Dec; 52(6):2195-2205. PubMed ID: 38842750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database.
    Wei L; Tian Y; Chen X; Guo X; Chen C; Zheng Y; Xu J; Ye X
    Int J Clin Pharm; 2023 Jun; 45(3):622-629. PubMed ID: 36848023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
    Zhao D; Long X; Zhou J; Wang J
    Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.
    Wu T; Zhang Y; Shi Y; Yu K; Zhao M; Liu S; Zhao Z
    Clin Drug Investig; 2022 Nov; 42(11):965-975. PubMed ID: 36175609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
    Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
    Orogun L; Chyou TY; Nishtala PS
    Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.